The biotechnology sector is on the brink of a radical transformation, catalyzed by the integration of artificial intelligence (AI) and innovations in personalized therapies. However, it faces major structural challenges, notably the "patent cliff" that threatens to reduce industry revenues by $400 billion. This massive patent expiration urges companies to innovate swiftly to offset revenue loss. The convergence of AI and biotechnology offers unprecedented opportunities but also raises ethical and security concerns, particularly regarding intellectual property and cyber risks.